| # | Drug | Count |
|---|---|---|
| 0 | CARBOPLATIN | 22 |
| 1 | PEMBROLIZUMAB | 21 |
| 2 | NIVOLUMAB | 19 |
| 3 | SORAFENIB | 18 |
| 4 | PACLITAXEL | 17 |
| 5 | PACLITAXEL (AIBUMIN-BOUND) | 14 |
| 6 | DOCETAXEL | 13 |
| 7 | DOCETAXEL ANHYDROUS | 13 |
| 8 | BEVACIZUMAB | 11 |
| 9 | ATEZOLIZUMAB | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | ETHIODIZED OIL | 3 | 0.0023 |
| 1 | SODIUM FLUORIDE AND POTASSIUM NITRATE | 1 | 0.0010 |
| 2 | SORAFENIB | 18 | 0.0009 |
| 3 | ZOLBETUXIMAB | 1 | 0.0007 |
| 4 | MITOMYCIN | 2 | 0.0005 |
| 5 | ERIBULIN MESYLATE | 2 | 0.0005 |
| 6 | REGORAFENIB | 6 | 0.0005 |
| 7 | FOSINOPIRL SODIUM | 1 | 0.0005 |
| 8 | DACTINOMYCIN | 1 | 0.0005 |
| 9 | TRABECTEDIN | 1 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Claudin 18.2-directed Cytolytic Antibody [EPC] | 1 | 0.0007 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 50 | 0.0005 |
| 2 | Actinomycin [EPC] | 1 | 0.0005 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 10 | 0.0002 |
| 4 | Microtubule Inhibitor [EPC] | 26 | 0.0002 |
| 5 | HER2/neu Receptor Antagonist [EPC] | 9 | 0.0001 |
| 6 | Radiographic Contrast Agent [EPC] | 3 | 0.0001 |
| 7 | Vitamin K [EPC] | 1 | 0.0001 |
| 8 | Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor [EPC] | 6 | 0.0001 |
| 9 | Platinum-based Drug [EPC] | 31 | 0.0001 |